Developmental Outcomes at 24 Months of Age in Toddlers Supplemented with Arachidonic Acid and Docosahexaenoic Acid: Results of a Double Blind Randomized, Controlled Trial.

Szczegóły
Abstrakt

Tytuł:: Developmental Outcomes at 24 Months of Age in Toddlers Supplemented with Arachidonic Acid and Docosahexaenoic Acid: Results of a Double Blind Randomized, Controlled Trial.
Autorzy:: Devlin AM; Department of Pediatrics, University of British Columbia, BC Children's Hospital Research Institute, A4-194 950 West 28th Ave, Vancouver, BC V5Z 4H4, Canada. .
Chau CMY; Department of Pediatrics, University of British Columbia, BC Children's Hospital Research Institute, A4-194 950 West 28th Ave, Vancouver, BC V5Z 4H4, Canada. .
Dyer R; Department of Pediatrics, University of British Columbia, BC Children's Hospital Research Institute, A4-194 950 West 28th Ave, Vancouver, BC V5Z 4H4, Canada. .
Matheson J; Department of Pediatrics, University of British Columbia, BC Children's Hospital Research Institute, A4-194 950 West 28th Ave, Vancouver, BC V5Z 4H4, Canada. .
McCarthy D; DSM Nutritional Products, Columbia, MD 21045, USA. .
Yurko-Mauro K; DSM Nutritional Products, Columbia, MD 21045, USA. .
Innis SM; Department of Pediatrics, University of British Columbia, BC Children's Hospital Research Institute, A4-194 950 West 28th Ave, Vancouver, BC V5Z 4H4, Canada. .
Grunau RE; Department of Pediatrics, University of British Columbia, BC Children's Hospital Research Institute, A4-194 950 West 28th Ave, Vancouver, BC V5Z 4H4, Canada.
Źródło:: Nutrients [Nutrients] 2017 Sep 06; Vol. 9 (9). Date of Electronic Publication: 2017 Sep 06.
Typ publikacji:: Journal Article; Randomized Controlled Trial
Język:: English
Imprint Name(s):: Original Publication: Basel, Switzerland : MDPI Publishing
MeSH Terms:: Child Development*
Arachidonic Acid/*administration & dosage
Docosahexaenoic Acids/*administration & dosage
Age Factors ; Arachidonic Acid/adverse effects ; Arachidonic Acid/blood ; British Columbia ; Child Language ; Child, Preschool ; Cognition ; Dietary Supplements/adverse effects ; Docosahexaenoic Acids/adverse effects ; Docosahexaenoic Acids/blood ; Double-Blind Method ; Erythrocytes/metabolism ; Female ; Humans ; Infant ; Intelligence ; Male ; Phosphatidylcholines/blood ; Phosphatidylethanolamines/blood ; Prospective Studies ; Psychomotor Performance ; Time Factors ; Treatment Outcome
References:: Pediatrics. 2012 Jun;129(6):1166-7. (PMID: 22641756)
Prostaglandins Leukot Essent Fatty Acids. 2017 Jan;116:9-18. (PMID: 28088293)
Biochim Biophys Acta. 2008 Apr;1781(4):200-12. (PMID: 18316044)
Pediatr Res. 2015 Jan;77(1-2):263-9. (PMID: 25314584)
Early Hum Dev. 2011 Mar;87(3):223-30. (PMID: 21295417)
Child Dev. 2004 Jul-Aug;75(4):1254-67. (PMID: 15260876)
Am J Clin Nutr. 2010 Apr;91(4):848-59. (PMID: 20130095)
Matern Child Nutr. 2011 Apr;7 Suppl 2:27-40. (PMID: 21366865)
Pediatr Res. 1997 Dec;42(6):826-34. (PMID: 9396565)
J Biotechnol. 1997 Aug 28;56(3):153-65. (PMID: 9304876)
Can J Public Health. 1999 Mar-Apr;90(2):114-9. (PMID: 10349218)
Adv Pediatr. 2016 Aug;63(1):453-71. (PMID: 27426911)
Pediatrics. 2008 Jun;121(6):1137-45. (PMID: 18519483)
Am J Clin Nutr. 2014 Mar;99(3):734S-41S. (PMID: 24500153)
Nutr J. 2015 Sep 30;14:101. (PMID: 26424477)
Am J Clin Nutr. 2013 Aug;98(2):536S-42S. (PMID: 23783296)
Prog Lipid Res. 2014 Jan;53:1-17. (PMID: 24334113)
Dev Sci. 2017 Sep;20(5):. (PMID: 27747986)
Nutrients. 2016 Apr 12;8(4):216. (PMID: 27077882)
Can J Public Health. 1996 Jul-Aug;87(4):231-6. (PMID: 8870300)
Am J Clin Nutr. 2013 Aug;98(2):403-12. (PMID: 23803884)
Prostaglandins Leukot Essent Fatty Acids. 2010 Apr-Jun;82(4-6):287-93. (PMID: 20207123)
Am J Clin Nutr. 2013 Mar;97(3):531-44. (PMID: 23364006)
PLoS One. 2014 Jan 10;9(1):e83764. (PMID: 24427279)
Am J Clin Nutr. 2005 May;81(5):1094-101. (PMID: 15883434)
Biol Psychiatry. 2016 Apr 1;79(7):516-25. (PMID: 26698193)
J Nutr. 1993 Oct;123(10):1668-75. (PMID: 8410357)
Prostaglandins Leukot Essent Fatty Acids. 2016 May;108:51-7. (PMID: 27154365)
Pediatr Res. 2011 Oct;70(4):406-10. (PMID: 21705959)
Dev Neuropsychol. 2009;34(2):159-74. (PMID: 19267293)
J Neurochem. 1998 Dec;71(6):2528-33. (PMID: 9832152)
Can J Diet Pract Res. 2005 Fall;66(3):176-82. (PMID: 16159411)
Contributed Indexing:: Keywords: arachidonic acid; docosahexaenoic acid; long chain polyunsaturated fatty acids; neurodevelopment; toddlers
Substance Nomenclature:: 0 (Phosphatidylcholines)
0 (Phosphatidylethanolamines)
25167-62-8 (Docosahexaenoic Acids)
27YG812J1I (Arachidonic Acid)
39382-08-6 (phosphatidylethanolamine)
Entry Date(s):: Date Created: 20170908 Date Completed: 20180521 Latest Revision: 20181113
Update Code:: 20240105
PubMed Central ID:: PMC5622735
DOI:: 10.3390/nu9090975
PMID:: 28878181
: Czasopismo naukowe

Full Text Finder

Little is known about arachidonic acid (ARA) and docosahexaenoic acid (DHA) requirements in toddlers. A longitudinal, double blind, controlled trial in toddlers ( n = 133) age 13.4 ± 0.9 months (mean ± standard deviation), randomized to receive a DHA (200 mg/day) and ARA (200 mg/day) supplement (supplement) or a corn oil supplement (control) until age 24 months determined effects on neurodevelopment. We found no effect of the supplement on the Bayley Scales of Infant and Toddler Development 3rd Edition (Bayley-III) cognitive and language composites and Beery-Buktenica Developmental Test of Visual-Motor Integration (Beery VMI) at age 24 months. Supplemented toddlers had higher RBC phosphatidylcholine (PC), phosphatidylethanolamine (PE), and plasma DHA and ARA compared to placebo toddlers at age 24 months. A positive relationship between RBC PE ARA and Bayley III Cognitive composite (4.55 (0.21-9.00), B (95% CI), p = 0.045) in supplemented boys, but not in control boys, was observed in models adjusted for baseline fatty acid, maternal non-verbal intelligence, and BMI z-score at age 24 months. A similar positive relationship between RBC PE ARA and Bayley III Language composite was observed for supplemented boys (11.52 (5.10-17.94), p < 0.001) and girls (11.19 (4.69-17.68), p = 0.001). These findings suggest that increasing the ARA status in toddlers is associated with better neurodevelopment at age 24 months.
Competing Interests: The authors declare no conflict of interest.

Informacja